- Home
- CALC vs VYNE Comparison
CALC vs VYNE Comparison
Compare CALC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- VYNE
- Stock Information
- Founded
- CALC 2011
- VYNE 2003
- Country
- CALC United States
- VYNE United States
- Employees
- CALC N/A
- VYNE N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- VYNE Health Care
- Exchange
- CALC Nasdaq
- VYNE Nasdaq
- Market Cap
- CALC 36.0M
- VYNE 35.7M
- IPO Year
- CALC N/A
- VYNE 2018
- Fundamental
- Price
- CALC $2.35
- VYNE $2.74
- Analyst Decision
- CALC Strong Buy
- VYNE Strong Buy
- Analyst Count
- CALC 5
- VYNE 2
- Target Price
- CALC $18.20
- VYNE $6.88
- AVG Volume (30 Days)
- CALC 31.5K
- VYNE 84.7K
- Earning Date
- CALC 03-27-2025
- VYNE 02-27-2025
- Dividend Yield
- CALC N/A
- VYNE N/A
- EPS Growth
- CALC N/A
- VYNE N/A
- EPS
- CALC N/A
- VYNE N/A
- Revenue
- CALC N/A
- VYNE $493,000.00
- Revenue This Year
- CALC N/A
- VYNE $28.30
- Revenue Next Year
- CALC N/A
- VYNE N/A
- P/E Ratio
- CALC N/A
- VYNE N/A
- Revenue Growth
- CALC N/A
- VYNE 39.27
- 52 Week Low
- CALC $2.05
- VYNE $1.57
- 52 Week High
- CALC $6.27
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- CALC 35.06
- VYNE 56.12
- Support Level
- CALC $2.36
- VYNE $2.39
- Resistance Level
- CALC $2.66
- VYNE $2.65
- Average True Range (ATR)
- CALC 0.24
- VYNE 0.20
- MACD
- CALC -0.02
- VYNE 0.05
- Stochastic Oscillator
- CALC 4.13
- VYNE 71.01
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.